RxDoctor Payments Data

Gayle Lombard

Family · Boaz, ALNPI 1942688320

Payments from drug & device makers

$7,604in general payments, 2019–2025

Across 487 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$594
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
  • Amgen$468
  • GSK$358
  • Sanofi-aventis U.S. LLC$334
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,604 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$16,659
Medicare patients
97
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$37,138
MounjaroTirzepatide31$32,407
TrulicityDulaglutide18$26,595
JardianceEmpagliflozin18$24,204
EliquisApixaban32$23,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$22,342
FarxigaDapagliflozin Propanediol13$16,275
LinzessLinaclotide20$13,494
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$11,150
Lagevrio (Eua)Molnupiravir12$10,463
Aimovig AutoinjectorErenumab-Aooe13$8,867
Tresiba Flextouch U-100Insulin Degludec16$6,647
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$6,451
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,625
Albuterol Sulfate HfaAlbuterol Sulfate175$4,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$142$59,00249 claims
Novo NordiskOzempic$594$37,13837 claims
GSKTrelegy Ellipta, Anoro Ellipta$358$27,96749 claims
Boehringer IngelheimJardiance$109$24,20418 claims
PfizerEliquis$168$23,27832 claims
AstraZenecaFarxiga$329$16,27513 claims
AbbVieLinzess$1,398$13,49420 claims
MerckLagevrio (Eua)$166$10,46312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →